"It is recommended that anti-obesity drugs should only be prescribed when the benefits of the treatment outweigh their risks. There are also invasive approaches such as gastrectomy to remove a part of stomach or liposuction surgery. However, these procedures can have profound harmful impacts on health, especially in the long term."
Yihai Cao, a professor in the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute in Stockholm and study leader on a team of researchers, who for the first time pinpointed a mechanism for the conversion of energy-storing white fat into energy-expending brown fat, a key finding that may lead to the discovery of new diabetes and obesity treatments

"Singapore's biotech ecosystem is becoming increasingly sophisticated, with licensing and acquisition deals and robust pipelines already in place. We now have an increasing number of made-in-Singapore drugs in clinical trials, and we have local biotech companies reaching valuations of hundreds of millions and achieving public listing. This is an exciting time to set up a biotech company in Singapore."
Benjamin Seet, executive director of the biomedical research council at A*STAR (The Agency for Science, Technology and Research)

"[We are excited] about the fact that we are identifying more and more partners that are truly committed to taking an approach to developing new options for cancer patients that is really biomarker driven and includes levering the richness of the molecular and genomic information insights that we can provide that make the development so much better – to de-risk it, to accelerate it and, ultimately, hopefully to create a whole new set of highly potent options for cancer patients to combat the disease."
Melanie Nallicheri, chief business officer and head of biopharmas, Foundation Medicine, which entered a broad partnership with Pfizer Inc. focused on development, regulatory support and commercialization of companion diagnostics